160 related articles for article (PubMed ID: 21345726)
1. Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study.
Ghobrial IM; Weller E; Vij R; Munshi NC; Banwait R; Bagshaw M; Schlossman R; Leduc R; Chuma S; Kunsman J; Laubach J; Jakubowiak AJ; Maiso P; Roccaro A; Armand P; Dollard A; Warren D; Harris B; Poon T; Sam A; Rodig S; Anderson KC; Richardson PG
Lancet Oncol; 2011 Mar; 12(3):263-72. PubMed ID: 21345726
[TBL] [Abstract][Full Text] [Related]
2. Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma.
Richardson PG; Weller E; Jagannath S; Avigan DE; Alsina M; Schlossman RL; Mazumder A; Munshi NC; Ghobrial IM; Doss D; Warren DL; Lunde LE; McKenney M; Delaney C; Mitsiades CS; Hideshima T; Dalton W; Knight R; Esseltine DL; Anderson KC
J Clin Oncol; 2009 Dec; 27(34):5713-9. PubMed ID: 19786667
[TBL] [Abstract][Full Text] [Related]
3. Phase-I/II study of bortezomib in combination with carboplatin and bevacizumab as first-line therapy in patients with advanced non-small-cell lung cancer.
Piperdi B; Walsh WV; Bradley K; Zhou Z; Bathini V; Hanrahan-Boshes M; Hutchinson L; Perez-Soler R
J Thorac Oncol; 2012 Jun; 7(6):1032-40. PubMed ID: 22534815
[TBL] [Abstract][Full Text] [Related]
4. Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma.
Richardson PG; Trudel S; Popat R; Mateos MV; Vangsted AJ; Ramasamy K; Martinez-Lopez J; Quach H; Orlowski RZ; Arnao M; Lonial S; Karanes C; Pawlyn C; Kim K; Oriol A; Berdeja JG; Rodríguez Otero P; Casas-Avilés I; Spirli A; Poon J; Li S; Gong J; Wong L; Lamba M; Pierce DW; Amatangelo M; Peluso T; Maciag P; Katz J; Pourdehnad M; Bahlis NJ;
N Engl J Med; 2023 Sep; 389(11):1009-1022. PubMed ID: 37646702
[TBL] [Abstract][Full Text] [Related]
5. A phase I study using bortezomib with weekly idarubicin for treatment of elderly patients with acute myeloid leukemia.
Howard DS; Liesveld J; Phillips GL; Hayslip J; Weiss H; Jordan CT; Guzman ML
Leuk Res; 2013 Nov; 37(11):1502-8. PubMed ID: 24075534
[TBL] [Abstract][Full Text] [Related]
6. Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma.
Kumar SK; Bensinger WI; Zimmerman TM; Reeder CB; Berenson JR; Berg D; Hui AM; Gupta N; Di Bacco A; Yu J; Shou Y; Niesvizky R
Blood; 2014 Aug; 124(7):1047-55. PubMed ID: 24904120
[TBL] [Abstract][Full Text] [Related]
7. A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma.
Voorhees PM; Manges RF; Sonneveld P; Jagannath S; Somlo G; Krishnan A; Lentzsch S; Frank RC; Zweegman S; Wijermans PW; Orlowski RZ; Kranenburg B; Hall B; Casneuf T; Qin X; van de Velde H; Xie H; Thomas SK
Br J Haematol; 2013 May; 161(3):357-66. PubMed ID: 23432640
[TBL] [Abstract][Full Text] [Related]
8. An Open-Label Phase I Study of Metformin and Nelfinavir in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple Myeloma.
Alodhaibi I; Ailawadhi S; Burbano GP; O'Brien PJ; Buadi FK; Hayman S; Kumar SK; Gonsalves WI
Clin Lymphoma Myeloma Leuk; 2024 May; 24(5):298-304. PubMed ID: 38220589
[TBL] [Abstract][Full Text] [Related]
9. Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody-drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1/2 study.
Daver NG; Montesinos P; DeAngelo DJ; Wang ES; Papadantonakis N; Todisco E; Sweet KL; Pemmaraju N; Lane AA; Torres-Miñana L; Thompson JE; Konopleva MY; Sloss CM; Watkins K; Bedse G; Du Y; Malcolm KE; Zweidler-McKay PA; Kantarjian HM
Lancet Oncol; 2024 Mar; 25(3):388-399. PubMed ID: 38423051
[TBL] [Abstract][Full Text] [Related]
10. Isatuximab, carfilzomib, lenalidomide, and dexamethasone in patients with newly diagnosed, transplantation-eligible multiple myeloma (SKylaRk): a single-arm, phase 2 trial.
O'Donnell E; Mo C; Yee AJ; Nadeem O; Laubach J; Rosenblatt J; Munshi N; Midha S; Cirstea D; Chrysafi P; Horick N; Richardson PG; Raje N
Lancet Haematol; 2024 Apr; ():. PubMed ID: 38677302
[TBL] [Abstract][Full Text] [Related]
11. Phase 1 clinical trial of bortezomib in adults with recurrent malignant glioma.
Phuphanich S; Supko JG; Carson KA; Grossman SA; Burt Nabors L; Mikkelsen T; Lesser G; Rosenfeld S; Desideri S; Olson JJ
J Neurooncol; 2010 Oct; 100(1):95-103. PubMed ID: 20213332
[TBL] [Abstract][Full Text] [Related]
12. A phase 1b dose-escalation study of carfilzomib in combination with thalidomide and dexamethasone in patients with relapsed/refractory systemic immunoglobulin light chain amyloidosis.
Ravichandran S; Hall A; Jenner M; Garg M; Kishore B; Lachmann H; Gillmore J; Pitchford A; Oughton JB; Mahmood S; Sachchithantham S; Hawkins P; Brown S; Wechalekar A
Amyloid; 2023 Sep; 30(3):290-296. PubMed ID: 37216268
[TBL] [Abstract][Full Text] [Related]
13. Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis.
Reece DE; Hegenbart U; Sanchorawala V; Merlini G; Palladini G; Bladé J; Fermand JP; Hassoun H; Heffner L; Kukreti V; Vescio RA; Pei L; Enny C; Esseltine DL; van de Velde H; Cakana A; Comenzo RL
Blood; 2014 Oct; 124(16):2498-506. PubMed ID: 25202139
[TBL] [Abstract][Full Text] [Related]
14. Hydroxyurea dose optimisation for children with sickle cell anaemia in sub-Saharan Africa (REACH): extended follow-up of a multicentre, open-label, phase 1/2 trial.
Aygun B; Lane A; Smart LR; Santos B; Tshilolo L; Williams TN; Olupot-Olupot P; Stuber SE; Tomlinson G; Latham T; Ware RE;
Lancet Haematol; 2024 Apr; ():. PubMed ID: 38701812
[TBL] [Abstract][Full Text] [Related]
15. A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma.
Zonder JA; Mohrbacher AF; Singhal S; van Rhee F; Bensinger WI; Ding H; Fry J; Afar DE; Singhal AK
Blood; 2012 Jul; 120(3):552-9. PubMed ID: 22184404
[TBL] [Abstract][Full Text] [Related]
16. Neuropathy and efficacy of once weekly subcutaneous bortezomib in multiple myeloma and light chain (AL) amyloidosis.
Sidana S; Narkhede M; Elson P; Hastings D; Faiman B; Valent J; Samaras C; Hamilton K; Liu HK; Smith MR; Reu FJ
PLoS One; 2017; 12(3):e0172996. PubMed ID: 28278302
[TBL] [Abstract][Full Text] [Related]
17. An Open-Label, Dose-Escalation Phase I Study of Anti-TYRP1 Monoclonal Antibody IMC-20D7S for Patients with Relapsed or Refractory Melanoma.
Khalil DN; Postow MA; Ibrahim N; Ludwig DL; Cosaert J; Kambhampati SR; Tang S; Grebennik D; Kauh JS; Lenz HJ; Flaherty KT; Hodi FS; Lawrence DP; Wolchok JD
Clin Cancer Res; 2016 Nov; 22(21):5204-5210. PubMed ID: 27797971
[TBL] [Abstract][Full Text] [Related]
18. Bortezomib: the evidence of its clinical impact in multiple myeloma.
Lancaster S
Core Evid; 2006; 1(4):265-77. PubMed ID: 22496681
[TBL] [Abstract][Full Text] [Related]
19. Bortezomib (Velcadetrade mark) in the Treatment of Multiple Myeloma.
Field-Smith A; Morgan GJ; Davies FE
Ther Clin Risk Manag; 2006 Sep; 2(3):271-9. PubMed ID: 18360602
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of belantamab mafodotin with pembrolizumab in patients with relapsed or refractory multiple myeloma.
Suvannasankha A; Bahlis N; Trudel S; Weisel K; Koenecke C; Oriol A; Voorhees PM; Alonso AA; Callander NS; Mateos MV; Reddy N; Hakim S; LaMacchia J; Patel N; Williams D; Jewell RC; Zhou X; Gupta I; Opalinska J; Nooka AK
Cancer; 2024 Apr; ():. PubMed ID: 38630908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
